Parallel phase 1 clinical trials in the US and in China:accelerating the test of avitinib in lung cancer as a novel inhibitor selectively targeting mutated EGFR and overcoming T790M-induced resistance
Xiao Xu;ACEA Biosciences Inc;ACEA Pharmaceutical Research;

..............page:285-287

Insight into early-phase trials for lung cancer in the United States
Jin-Ji Yang;Yi-Long Wu;Guangdong Lung Cancer Institute;Guangdong General Hospital;Guangdong Academy of Medical Sciences;

..............page:288-294

Predictive biomarkers in precision medicine and drug development against lung cancer
Bingliang Fang;Reza J Mehran;John V Heymach;Stephen G Swisher;Department of Thoracic and Cardiovascular Surgery;The University of Texas MD Anderson Cancer Center;Department of Thoracic and Head/Neck Medical Oncology;The University of Texas MD Anderson Cancer Center;

..............page:295-309

Targeted therapies for patients with advanced NSCLC harboring wild-type EGFR:what’s new and what’s enough
Fei Zhou;Cai-Cun Zhou;Department of Medical Oncology;Shanghai Pulmonary Hospital;Tongji University School of Medicine;

..............page:310-319

Global efforts in conquering lung cancer in China
Li Van;Li Xu;The US Chinese Anti-Cancer Association;Beijing Cancer Hospital and Institute;Peking University School of Oncology;Jiangsu Hengrui Medicine Co.;LTD;

..............page:320-322

Early-Phase Oncology Research Training(EFFORT) program:a Hengrui-USCACA joint scholarship
Li Yan;Li Xu;The US Chinese Anti-Cancer Association;Beijing Cancer Hospital and Institute;Peking University School of Oncology;Jiangsu Hengrui Medicine Co.;Ltd;

..............page:323-324

Information for Authors

..............page:325